Loading
Latest filing published 13 Oct 2026 for Retension Pharmaceuticals, Inc.. Read the official filing
No signal scores available.
Paul Sweetnam discloses dealings in Retension Pharmaceuticals, Inc. to SEC (Form 4). We count 2 filings, every one of them for a trade on 13 October 2026.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 13 October 2026 with a transaction in Retension Pharmaceuticals, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations